Adeoye Y. Olukotun

CIK: 0001242615

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (54.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (36.4%)

Compensation grants

Other (G, F, J, C, D, …)1 (9.1%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

Director

TNXP

Tonix Pharmaceuticals Holding Corp.

Director

Discretionary Trading P&L

Holdings

Transaction History (11 total)

ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Aug 18, 2026
Sale(S)
Direct
2K shares at avg. $86.96$174K
TNXP
Tonix Pharmaceuticals Holding Corp.
May 12, 2026
Award(A)
Stock Option
Direct
22.7K shares-
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 19, 2025
Sale(S)
Direct
827 shares at avg. $68.48$57K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 19, 2025
Sale(S)
Direct
6.1K shares at avg. $68.04$414K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 19, 2025
Sale(S)
Direct
3.1K shares at avg. $66.70$206K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 16, 2025
Award(A)
Direct
7.8K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
May 13, 2025
Award(A)
Stock Option
Direct
10K shares-
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Jan 23, 2025
Sale(S)
Direct
959 shares at avg. $21.00$20K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 27, 2024
Sale(S)
Direct
2.9K shares at avg. $20.00$57K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 18, 2024
Award(A)
Direct
16.7K shares at avg. $22.99$385K
TNXP
Tonix Pharmaceuticals Holding Corp.
Jun 10, 2024
Other(J)
Direct
1 shares at avg. $1.91$1.551

		Type	Shares	Price		Ownership
Aug 18, 2026	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	2,000	$86.96	$173,920	Direct
May 12, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	22,700	-	-	Direct
Dec 19, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	827	$68.48	$56,633	Direct
Dec 19, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	6,083	$68.04	$413,887	Direct
Dec 19, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	3,090	$66.70	$206,103	Direct
Dec 16, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Award(A)	7,819	-	-	Direct
May 13, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	10,000	-	-	Direct
Jan 23, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	959	$21.00	$20,139	Direct
Dec 27, 2024	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	2,850	$20.00	$57,000	Direct
Dec 18, 2024	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Award(A)	16,733	$22.99	$384,692	Direct
Jun 10, 2024	TNXP Tonix Pharmaceuticals Holding Corp.	Other(J)	1	$1.91	$2	Direct

1-11 of 11 transactions

About OLUKOTUN ADEOYE Y

OLUKOTUN ADEOYE Y (SEC CIK 0001242615) files insider reports with the SEC as Director of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) and Director of Tonix Pharmaceuticals Holding Corp. (TNXP).

Signal8 holds 9 ownership filings by OLUKOTUN ADEOYE Y, all Form 4s, filed between Dec 20, 2024 and Aug 20, 2026. Those filings report 11 transactions, from Jun 10, 2024 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on OLUKOTUN ADEOYE Y's filings is in PASADENA, CA.

Recent filings by OLUKOTUN ADEOYE Y

Aug 18, 2026: Open-market sale of ARWR shares (Form 4, code S).
May 12, 2026: Grant or award of TNXP derivative securities (Form 4, code A).
Dec 19, 2025: Open-market sales of ARWR shares (3 lines, Form 4, code S).
Dec 16, 2025: Grant or award of ARWR shares (Form 4, code A).
May 13, 2025: Grant or award of TNXP derivative securities (Form 4, code A).

Other insiders filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

PERRY MICHAEL S, Director
Cohen Matthew Gregory, Director
Lu Hongbo, Director
Apel Daniel Joseph, Chief Financial Officer
Hamilton James C, Chief Medical Officer
O'Brien Patrick, COO

How to read Form 4 transaction codes